Global Driven by increased demand from Big Pharma, mid-caps, and biotechs for outsourcing services, the USD 70 billion global contract research organisation (CRO) market is predicted to grow at a CAGR of between 11 and 12 percent over the next five to seven years, with differing estimates placing its total size…
China As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market include Chinese firms’ deals to manufacture generic versions of Pfizer’s COVID antiviral, Kintor’s 229 percent share price leap after positive…
Global UNICEF is forecasting that between 16.8 billion and 20.9 billion COVID-19 vaccine doses will be produced in 2022. The Economist Intelligence Unit highlights the drivers of this incredible demand as the fact that booster shots will be needed to counter new variants; the increased number of countries requesting the Pfizer…
India The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to 19 Indian pharmaceutical firms for the generic version of Pfizer’s oral antiviral COVID-19 pill. COVID-19 vaccine booster shots now…
Italy Organon Italy’s Alper Alptekin introduces the newly formed women’s health company, his priorities for the Italian affiliate, and how improvements in women’s health can improve gender equality and give women the ability to be stronger, more vocal, and more independent. While Organon’s portfolio is meeting the needs of women,…
Global Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what antibiotics manufacturers are doing about it. Last month, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial…
Japan Japanese firm Kirin, part of the Mitsubishi Group and best known for its brewing operations, has pledged to invest JPY 100 billion (USD 870 million) into its healthcare/pharma operations amid a slowdown in the Japanese beer market. Beer Today, Gone Tomorrow Japan’s rapidly ageing population and the effects of…
Spain Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be…
Global Pharmaceutical sales are expected to rise by 4.9 percent in 2022 according to the Economist Intelligence Unit (EIU) with the US continuing to lead the world in pharmaceutical sales numbers. This rise will be driven partly by COVID-19 vaccine sales and the development of other anti-COVID treatments and will also…
Europe Having moved early on a promising phase II monoclonal antibody, Almirall is inching closer to entering the Sanofi-dominated European market for eczema after posting, along with Eli Lilly, positive phase III results for Lebrikizumab. The Catalan company says it is on track for a 2023 launch on the continent; Lilly…
Global Exactly five months after concluding that it was the right time to “monetize” its investment in a cross-town rival – providing Roche “full strategic flexibility” in the process – Novartis has announced a major restructuring; this time, too, citing financial motives. The Swiss giant – fifth in the global…
Global In 2022 global healthcare will continue to feel the effects of the pandemic and although COVID-19 has become less virulent, with the global death rate down to 0.4 percent from an initial peak of about three percent, new variants are still set to emerge this year. At the Economist Intelligence…
See our Cookie Privacy Policy Here
